Dyadic International, Inc. held its 2026 Annual Meeting of Shareholders on June 18, 2026. Shareholders approved the board of directors' authorization to effect a discretionary reverse stock split within a range specified in the company's Proxy Statement. Additionally, Seth J. Herbst, M.D. was elected as a Class I director to serve until the 2029 Annual Meeting. The meeting also included the ratification of Crowe LLP as the independent registered public accounting firm and an advisory vote on executive compensation. Dyadic International, Inc. is a healthcare company focused on molecular diagnostics.
